In this issue:
KEYNOTE-057: Pembrolizumab monotherapy for BCG-unresponsive NMIBC
KEYNOTE-361: No benefit to frontline pembrolizumab for unresectable or metastatic UC
TROPHY-U-01 finds sacituzumab govitecan efficacious in metastatic UC
No survival benefit to the addition of bevacizumab to chemotherapy combination in advanced UC
Genomic comparison of UTUC and bladder tumours
Metastasis-directed therapies for molecularly-defined oligorecurrent prostate cancer
PROSTAGE: 18F-PSMA-PET/CT imaging superior for initial metastasis detection in high-risk prostate cancer
Robotic post-chemotherapy RPLND may reduce morbidity compared to open surgery in testicular cancer
Checkpoint inhibition therapy elicits similar outcomes in upper tract and bladder UC
Limited primary renal tumour response in patients treated with nivolumab
Please login below to download this issue (PDF)